NervGen Pharma (TSXV:NGEN) ROCE % : -2,066.75% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NervGen Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was -2,066.75%.

NervGen Pharma ROCE % Historical Data

The historical data trend for NervGen Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma ROCE % Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-228.74

-190.39

-111.94

-132.62

-380.84

NervGen Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-147.16	-159.14	-214.80	-265.88	-2,066.75

NervGen Pharma ROCE % Calculation

NervGen Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-22.382	/	( ( (23.875 - 10.217)	+	(13.236 - 15.14) )	/ 2 )
	=	-22.382	/	( (13.658	+	-1.904)	/ 2 )
	=	-22.382	/	5.877
	=	-380.84 %

NervGen Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-34.432	/	( ( (16.36 - 11.124)	+	(13.236 - 15.14) )	/ 2 )
	=	-34.432	/	( ( 5.236	+	-1.904 )	/ 2 )
	=	-34.432	/	1.666
	=	-2,066.75 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

NervGen Pharma (TSXV:NGEN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NervGen Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma (TSXV:NGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NGENF:USA 9UA:Germany

Address

2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6

Website

https://www.nervgen.com

NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

Executives

John Ruffolo

Director

NervGen Pharma (TSXV:NGEN) Headlines

No Headlines